Thus, the diverging effects of Rapa and SAP observed in glioma cells after 6 days of treatment can be well explained by the fact that SAP, by increasing both LC3A II and beclin1, induces a full activation of autophagy, whereas the reduction in beclin-1 production, associated with Rapa treatment, tends to counter-balance the increase in LC3A II, resulting in a lower level of autophagy. The gene discussed is TRERF1; the disease is central nervous system cancer.